Xylem Earnings Call Transcripts
Fiscal Year 2025
-
Record 2025 results with strong revenue, margin, and EPS growth. 2026 guidance calls for continued margin expansion and EPS growth, with a short-term revenue headwind from portfolio simplification and ongoing China weakness. Capital deployment focuses on core investment and M&A.
-
Q3 saw robust revenue and margin growth across all segments, with record EBITDA margin and strong EPS gains. Full-year guidance was raised for revenue, margin, and EPS, while portfolio optimization and simplification efforts continue to drive performance.
-
Q2 saw strong organic revenue growth, record adjusted EBITDA margin, and raised full-year guidance for both revenue and EPS. Segment performance was robust, with margin expansion driven by productivity and simplification, while tariff and macro uncertainties remain watch items.
-
The meeting covered board elections, auditor ratification, and executive compensation approval, with all proposals except the shareholder special meeting threshold passing. Strong financial results and strategic initiatives were highlighted, and management addressed tariff concerns.
-
Q1 2025 delivered strong revenue and margin growth, with all segments contributing and EPS up 14% year-over-year. Full-year guidance for revenue and EPS is reaffirmed, with tariff impacts managed through pricing and supply chain actions. M&A and portfolio optimization remain strategic priorities.
Fiscal Year 2024
-
Record 2024 results with revenue up 6%, EBITDA margin up 170 bps, and double-digit EPS growth. 2025 guidance calls for 3–4% organic revenue growth, 70–120 bps margin expansion, and 8% EPS growth at midpoint, with restructuring and portfolio simplification underway.
-
Record Q3 profitability driven by operational discipline, strong orders, and successful Evoqua integration. Revenue growth moderated due to project timing, but margin expansion and robust cash flow support a positive outlook. Idrica majority stake and leadership changes position the company for future growth.
-
Q2 delivered strong organic growth, margin expansion, and 11% EPS growth, led by MCS and WSS segments. Full-year guidance for revenue, margin, and EPS was raised, with Evoqua integration and cost synergies on track. Demand remains robust across most end markets.
-
Acquisition integration is improving, with Sensus and Evoqua showing margin and synergy gains. Operational discipline, strategic pricing, and the 80/20 program are driving margin expansion, while strong financials support up to $10 billion in capital deployment through 2027.